Protagonist Therapeutics, Inc.

NasdaqGM:PTGX Stok Raporu

Piyasa değeri: US$2.8b

Protagonist Therapeutics Yönetim

Yönetim kriter kontrolleri 4/4

Protagonist Therapeutics CEO'su Dinesh Patel, Dec2008 tarihinde atandı, in görev süresi 15.92 yıldır. in toplam yıllık tazminatı $ 7.07M olup, şirket hissesi ve opsiyonları dahil olmak üzere 9.3% maaş ve 90.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.7% ine doğrudan sahiptir ve bu hisseler $ 19.43M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.8 yıl ve 9.8 yıldır.

Anahtar bilgiler

Dinesh Patel

İcra Kurulu Başkanı

US$7.1m

Toplam tazminat

CEO maaş yüzdesi9.3%
CEO görev süresi15.9yrs
CEO sahipliği0.7%
Yönetim ortalama görev süresi3.8yrs
Yönetim Kurulu ortalama görev süresi9.8yrs

Son yönetim güncellemeleri

Recent updates

The Prognosis For Protagonist Therapeutics: Solid Prospects, But Stock Is Pricey

Oct 16

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't

Apr 13
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't

Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise

Feb 25

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Dec 28
We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Jul 04
We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts

Mar 20
Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts

An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued

Feb 06
An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued

We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate

Jun 15
We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate

Protagonist: Too Many Red Flags

Jun 08

Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%

May 11
Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%

Protagonist Is Still Being Undervalued Like There's Real Risk

Feb 01

Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth

Jan 04
Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates

Aug 06
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year

Jun 19
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year

Protagonist Therapeutics closes $132M capital raise

Jun 18

Protagonist wins FDA Breakthrough Therapy Designation for blood cancer therapy

Jun 03

This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet

May 21
This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet

Protagonist EPS beats by $0.03, beats on revenue

May 04

CEO Tazminat Analizi

Dinesh Patel'un ücretlendirmesi Protagonist Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

US$171m

Jun 30 2024n/an/a

US$170m

Mar 31 2024n/an/a

US$162m

Dec 31 2023US$7mUS$655k

-US$79m

Sep 30 2023n/an/a

-US$140m

Jun 30 2023n/an/a

-US$138m

Mar 31 2023n/an/a

-US$140m

Dec 31 2022US$6mUS$630k

-US$127m

Sep 30 2022n/an/a

-US$130m

Jun 30 2022n/an/a

-US$133m

Mar 31 2022n/an/a

-US$122m

Dec 31 2021US$6mUS$600k

-US$126m

Sep 30 2021n/an/a

-US$108m

Jun 30 2021n/an/a

-US$81m

Mar 31 2021n/an/a

-US$70m

Dec 31 2020US$2mUS$565k

-US$66m

Sep 30 2020n/an/a

-US$65m

Jun 30 2020n/an/a

-US$73m

Mar 31 2020n/an/a

-US$83m

Dec 31 2019US$2mUS$545k

-US$77m

Sep 30 2019n/an/a

-US$74m

Jun 30 2019n/an/a

-US$66m

Mar 31 2019n/an/a

-US$45m

Dec 31 2018US$4mUS$520k

-US$39m

Sep 30 2018n/an/a

-US$28m

Jun 30 2018n/an/a

-US$24m

Mar 31 2018n/an/a

-US$31m

Dec 31 2017US$790kUS$475k

-US$37m

Tazminat ve Piyasa: Dinesh 'ın toplam tazminatı ($USD 7.07M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 6.56M ).

Tazminat ve Kazançlar: Dinesh 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Dinesh Patel (67 yo)

15.9yrs

Görev süresi

US$7,067,572

Tazminat

Dr. Dinesh V. Patel, Ph D., has been the Chief Executive Officer, President and Director at Protagonist Therapeutics, Inc. since December 2008 and serves as its Secretary. He served as Interim Chief Financ...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Dinesh Patel
CEO, President15.9yrsUS$7.07m0.70%
$ 19.4m
Asif Ali
Executive VP & Chief Financial Officer2.6yrsUS$1.40m0%
$ 0
Suneel Gupta
Chief Development Officer5.8yrsUS$2.22m0.25%
$ 6.9m
Mark Smythe
Founder & VP Technology3.8yrsVeri yokVeri yok
Mohammad Masjedizadeh
Executive VP & Chief Technical Officer3.8yrsVeri yokVeri yok
Matthew Gosling
Executive VP & General Counsel4.2yrsVeri yokVeri yok
Carena Spivey
Head of HR & Senior VP of Human Resources3.8yrsVeri yokVeri yok
Ashok Bhandari
Executive VP & Chief Drug Discovery and Preclinical Development Officer3.8yrsVeri yokVeri yok
Carter King
Executive Vice President of Business Development3.6yrsVeri yokVeri yok
Abha Bommireddi
Executive Vice President of Portfolio & Program Management3.8yrsVeri yokVeri yok
Arturo Molina
Chief Medical Officer2yrsVeri yok0.013%
$ 347.8k
Samuel Saks
Clinical Development Advisor3.8yrsVeri yokVeri yok

3.8yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim: PTGX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Dinesh Patel
CEO, President15.9yrsUS$7.07m0.70%
$ 19.4m
Harlan Weisman
Clinical Advisor9.8yrsVeri yokVeri yok
Lewis Williams
Independent Director7.4yrsUS$351.52k0%
$ 0
Chaitan Khosla
Chairman of Scientific Advisory Board9.8yrsUS$188.07kVeri yok
Harold Selick
Independent Chairman15.8yrsUS$395.27k0.047%
$ 1.3m
William Waddill
Independent Director8.3yrsUS$364.02k0.020%
$ 557.4k
Charles Craik
Scientific Advisorno dataVeri yokVeri yok
Mark Gallop
Scientific Advisorno dataVeri yokVeri yok
Wayne Lencer
Clinical Advisorno dataVeri yokVeri yok
Aida Habtezion
Clinical Advisorno dataVeri yokVeri yok
Ellen Scherl
Clinical Advisorno dataVeri yokVeri yok
Bryan Giraudo
Independent Director6.5yrsUS$356.52k0.030%
$ 836.2k

9.8yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PTGX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.8 yıldır).